Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
about
Feasibility of chemosensitivity testing in soft tissue sarcomasTrabectedin for Soft Tissue Sarcoma: Current Status and Future PerspectivesTrabectedin in soft tissue sarcomasTrabectedin and its potential in the treatment of soft tissue sarcoma.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Role of trabectedin in the treatment of soft tissue sarcomaClinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patientsA comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicityA phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.Dose escalation methods in phase I cancer clinical trials.The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.Update on the role of trabectedin in the treatment of intractable soft tissue sarcomasEcteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials†.
P2860
Q24796008-C44B78F2-E320-46E8-86CA-17F05EA27BC7Q26745502-A13E9E8F-CA47-4564-ABD3-8A7AEDA69529Q28085505-40A43452-3A36-4AFE-B4F9-9C03FEAF2208Q33380903-2DCF6BC1-D0F0-4080-B730-E9A5CE76B177Q33381641-B29F9A12-CC65-4DFE-96D6-742B2E59ABFAQ33916011-3737D3DA-A126-4696-996C-B648206CCB76Q33921802-DA985639-4892-4031-9046-FF17F32C2A0BQ34061855-CC5A28C0-9A5A-4D32-8DD4-2D46030C503BQ34578850-17CAEC80-84F8-4332-9C1B-22AA94785A23Q35676502-5A070E6A-01B9-48D6-AC9A-56E426D6C196Q35996144-B385F4E7-CA02-4C5D-89CC-B20060546557Q36610752-9333D8F0-A912-4441-90E5-7DE6056DCF27Q36948681-6F6DD6CB-A674-4549-8361-5E5F871439DAQ37005569-03047FBC-8CEE-4F87-A86A-BB4B71011B8CQ37198192-B5DD0801-5AF0-4A97-B864-7BFEBF000B4AQ37389930-70E31DBF-F8A2-4C1B-B7A1-C9638B90F952Q37669484-0F6C0B6B-083D-4E0D-A3A4-9467379D3AF0Q38255906-50E5D50A-37E6-414F-B20B-46C6AE241FF1Q55712396-2D240531-B86A-4B17-AA1E-1002C2D493B8
P2860
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phase I and pharmacokinetic st ...... ients with solid malignancies.
@ast
Phase I and pharmacokinetic st ...... ients with solid malignancies.
@en
type
label
Phase I and pharmacokinetic st ...... ients with solid malignancies.
@ast
Phase I and pharmacokinetic st ...... ients with solid malignancies.
@en
prefLabel
Phase I and pharmacokinetic st ...... ients with solid malignancies.
@ast
Phase I and pharmacokinetic st ...... ients with solid malignancies.
@en
P2093
P1476
Phase I and pharmacokinetic st ...... ients with solid malignancies.
@en
P2093
A J Fischman
M V Seiden
P304
P407
P577
2001-02-01T00:00:00Z